Skip to main content
Premium Trial:

Request an Annual Quote

Gentris Licenses LGC s CYP450 Polymorphism for Use in Genotyping Service

NEW YORK, June 7 (GenomeWeb News) - Gentris has taken a non-exclusive license from LGC for a common drug-metabolism polymorphism, the companies said today.

 

According to the terms of the agreement, Gentris gains the rights to make, use, and sell diagnostic products and services that rely on LGC's CYP450 2D6*4 polymorphism.

 

Gentris plans to use the polymorphism in its genotyping service, CEO Michael Murphy said.

 

LGC is the exclusive licensor of the polymorphism.

 

The *4 polymorphism is the most common CYP450 2D6 polymorphism in Caucasians, and the 2D6 gene itself is believed to be involved in the metabolism of about 30 percent of approved drugs.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.